OBJECTIVE: Oestradiol (E2) and its metabolites 2-hydroxyoestrone (2-OHE1) and 16alpha-hydroxyoestrone (16alpha-OHE1) are thought to curtail the greater oxidative stress found in the development and progression of disease conditions including atherosclerosis. We related oestrogen levels to F(2a)-isoprostane levels, a biomarker of oxidative stress. DESIGN AND PARTICIPANTS: Data were obtained from 1647 women, aged 47-57 years, participating in the fifth annual follow-up of the Study of Women's Health Across the Nation (SWAN), a study of the menopausal transition. MEASUREMENTS: Serum E2 and urinary 2-OHE1 and 16alpha-OHE1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and urinary F(2a)-isoprostanes were measured by enzyme immunoassay (EIA). RESULTS: F(2a)-isoprostane concentrations were elevated in women who smoked, a behaviour associated with increased oxidative stress, but not in stages of the natural menopause. Mean F(2a)-isoprostane concentrations among pre- and postmenopausal women who smoked were 1082 and 1064 pg/ml, respectively, values double those in pre- (343 pg/ml) and postmenopausal (379 pg/ml) nonsmoking women. 2-OHE1 and F(2a)-isoprostane concentrations were positively and highly correlated (partial correlations rho(Y|X) = 0.44 and rho(Y|X) = 0.43 in pre- and postmenopausal women, respectively). Similarly, 16alpha-OHE1 concentrations were positively and highly correlated with F(2a)-isoprostane concentrations (rho(Y|X) = 0.52 and rho(Y|X) = 0.59 in pre- and postmenopausal women, respectively). E2 was significantly correlated with F(2a)-isoprostanes only in postmenopausal women (rho(Y|X) = 0.20). Associations were adjusted for age, body mass index (BMI), race/ethnicity, lipids, physical activity level and alcohol consumption. CONCLUSIONS: This study does not support the commonly held hypothesis that levels of endogenous E2 or its oestrone metabolites favourably modify oxidative stress by decreasing F2(a)-isoprostane levels.
OBJECTIVE:Oestradiol (E2) and its metabolites 2-hydroxyoestrone (2-OHE1) and 16alpha-hydroxyoestrone (16alpha-OHE1) are thought to curtail the greater oxidative stress found in the development and progression of disease conditions including atherosclerosis. We related oestrogen levels to F(2a)-isoprostane levels, a biomarker of oxidative stress. DESIGN AND PARTICIPANTS: Data were obtained from 1647 women, aged 47-57 years, participating in the fifth annual follow-up of the Study of Women's Health Across the Nation (SWAN), a study of the menopausal transition. MEASUREMENTS: Serum E2 and urinary 2-OHE1 and 16alpha-OHE1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and urinary F(2a)-isoprostanes were measured by enzyme immunoassay (EIA). RESULTS:F(2a)-isoprostane concentrations were elevated in women who smoked, a behaviour associated with increased oxidative stress, but not in stages of the natural menopause. Mean F(2a)-isoprostane concentrations among pre- and postmenopausal women who smoked were 1082 and 1064 pg/ml, respectively, values double those in pre- (343 pg/ml) and postmenopausal (379 pg/ml) nonsmoking women. 2-OHE1 and F(2a)-isoprostane concentrations were positively and highly correlated (partial correlations rho(Y|X) = 0.44 and rho(Y|X) = 0.43 in pre- and postmenopausal women, respectively). Similarly, 16alpha-OHE1 concentrations were positively and highly correlated with F(2a)-isoprostane concentrations (rho(Y|X) = 0.52 and rho(Y|X) = 0.59 in pre- and postmenopausal women, respectively). E2 was significantly correlated with F(2a)-isoprostanes only in postmenopausal women (rho(Y|X) = 0.20). Associations were adjusted for age, body mass index (BMI), race/ethnicity, lipids, physical activity level and alcohol consumption. CONCLUSIONS: This study does not support the commonly held hypothesis that levels of endogenous E2 or its oestrone metabolites favourably modify oxidative stress by decreasing F2(a)-isoprostane levels.
Authors: K W Hinchcliff; G A Reinhart; R DiSilvestro; A Reynolds; A Blostein-Fujii; R A Swenson Journal: Am J Vet Res Date: 2000-05 Impact factor: 1.156
Authors: MaryFran R Sowers; Sybil Crawford; Daniel S McConnell; John F Randolph; Ellen B Gold; Margaret K Wilkin; Bill Lasley Journal: J Nutr Date: 2006-06 Impact factor: 4.798
Authors: J L Cracowski; C Cracowski; G Bessard; J L Pepin; J Bessard; C Schwebel; F Stanke-Labesque; C Pison Journal: Am J Respir Crit Care Med Date: 2001-09-15 Impact factor: 21.405
Authors: V J Victorino; C Panis; F C Campos; R C Cayres; A N Colado-Simão; S R Oliveira; A C S A Herrera; A L Cecchini; R Cecchini Journal: Age (Dordr) Date: 2012-05-28
Authors: C Kim; S D Harlow; C A Karvonen-Gutierrez; J F Randolph; M Helmuth; S Kong; B Nan; R Carlos Journal: Diabet Med Date: 2013-06-07 Impact factor: 4.359
Authors: Enrique F Schisterman; Audrey J Gaskins; Sunni L Mumford; Richard W Browne; Edwina Yeung; Maurizio Trevisan; Mary Hediger; Cuilin Zhang; Neil J Perkins; Kathleen Hovey; Jean Wactawski-Wende Journal: Am J Epidemiol Date: 2010-08-01 Impact factor: 4.897
Authors: Hui-Chen Wu; Laura A Brennan; Mandy Goldberg; Wendy K Chung; Ying Wei; Regina M Santella; Mary Beth Terry Journal: Free Radic Res Date: 2020-09-10
Authors: Carole B Rudra; Jean Wactawski-Wende; Kathleen M Hovey; Richard W Browne; Cuilin Zhang; Mary L Hediger; Enrique F Schisterman Journal: Med Sci Sports Exerc Date: 2011-05 Impact factor: 5.411
Authors: Arnaldo Lopez-Ruiz; Julio Sartori-Valinotti; Licy L Yanes; Radu Iliescu; Jane F Reckelhoff Journal: Am J Physiol Heart Circ Physiol Date: 2008-06-20 Impact factor: 4.733
Authors: Matthew B Crist; Vlada V Melekhin; Aihua Bian; Ayumi Shintani; Ginger L Milne; Asha R Kallianpur; Leigh A Dageforde; David W Haas; Todd Hulgan Journal: J Acquir Immune Defic Syndr Date: 2013-12-01 Impact factor: 3.731